Genix Pharmaceuticals Corporation
GENPF · OTC
10/31/2024 | 10/31/2023 | 10/31/2022 | 10/31/2021 | |
|---|---|---|---|---|
| Market Cap | $3 | $2 | $4 | $9 |
| - Cash | $0 | $0 | $0 | $0 |
| + Debt | $1 | $1 | $0 | $0 |
| Enterprise Value | $4 | $3 | $5 | $9 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | -67.2% | – | – | – |
| Gross Profit | $0 | $0 | -$1 | -$1 |
| % Margin | 32% | 26.4% | – | – |
| EBITDA | $0 | -$4 | -$0 | -$1 |
| % Margin | 1,211.3% | -30,743.3% | – | – |
| Net Income | -$0 | -$4 | -$1 | -$2 |
| % Margin | -1,806.9% | -35,600.3% | – | – |
| EPS Diluted | -0.001 | -0.074 | -0.018 | -0.028 |
| % Growth | 98.4% | -309.9% | 35.1% | – |
| Operating Cash Flow | -$0 | -$0 | -$0 | -$0 |
| Capital Expenditures | $0 | $0 | -$0 | $0 |
| Free Cash Flow | -$0 | -$0 | -$0 | -$0 |